Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3226964#aggregation> ?p ?o. }
Showing items 1 to 41 of
41
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B604273.
- aggregation creator B604274.
- aggregation creator B604275.
- aggregation creator B604276.
- aggregation creator B604277.
- aggregation creator B604278.
- aggregation creator B604279.
- aggregation creator B604280.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2012".
- aggregation format "application/pdf".
- aggregation hasFormat 3226964.bibtex.
- aggregation hasFormat 3226964.csv.
- aggregation hasFormat 3226964.dc.
- aggregation hasFormat 3226964.didl.
- aggregation hasFormat 3226964.doc.
- aggregation hasFormat 3226964.json.
- aggregation hasFormat 3226964.mets.
- aggregation hasFormat 3226964.mods.
- aggregation hasFormat 3226964.rdf.
- aggregation hasFormat 3226964.ris.
- aggregation hasFormat 3226964.txt.
- aggregation hasFormat 3226964.xls.
- aggregation hasFormat 3226964.yaml.
- aggregation isPartOf urn:issn:1068-9265.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study".
- aggregation abstract "Up to 25% of patients with metastatic colorectal cancer (CRC) present with peritoneal carcinomatosis (PC) as the only site of metastases. Complete cytoreductive surgery (CCRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) aims for locoregional disease control and long-term survival. Oxaliplatin is effective for treating advanced CRC. This study assesses the safety and efficacy of CCRS with HIPEC with oxaliplatin for patients with PC of CRC. A Belgian prospective multicenter registry was performed to monitor perioperative morbidity and assess mortality, disease-free survival (DFS), and overall survival (OS). Forty-eight consecutive patients underwent CCRS (R0/1) with HIPEC (male/female ratio 17/31, median age 60 years, range 24-76 years). Median PC index was 11 (range 1-22). Median operation time was 460 (range 125-840) min, with a median blood loss of 475 (range 2-6,000) ml. Thirty-day mortality was 0%. Complication rate (any grade) was 52.1%. Anastomotic leakage occurred in 10.4% of patients, bleeding in 6.3%, and bowel perforation in 2.1%. Median hospital stay was 20 (range 5-65) days. At median follow-up of 22.7 (range 3.2-55.7) months, OS was 97.9% [95% confidence interval (CI) 86.1-99.7] at 1 year and 88.7% (95% CI 73.6-95.4) at 2 years. DFS at 1 year was 65.8% (95% CI 52.3-76.2) and 45.5% (95% CI 34.3-55.9) at 2 years. Median time until recurrence was 19.8 months (95% CI 12-upper limit not defined). Only after dichotomizing PC index was a significant difference in OS found between low and high PC index. CCRS followed by HIPEC with oxaliplatin for PC from CRC can be implemented with acceptable morbidity. Long-term DFS and OS can be achieved in selected patients.".
- aggregation authorList BK959383.
- aggregation endPage "2194".
- aggregation issue "7".
- aggregation startPage "2186".
- aggregation volume "19".
- aggregation aggregates 3227058.
- aggregation isDescribedBy 3226964.
- aggregation similarTo s10434-012-2264-z.
- aggregation similarTo LU-3226964.